Maternal immunization

New England Journal of Medicine

Volumn 376, Issue 13, 2017, Pages 1256-1267

  Omer, Saad B ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; ESTRADIOL; INFLUENZA VACCINE; PROGESTERONE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; STREPTOCOCCUS VACCINE; PERTUSSIS VACCINE; VACCINE;

CELLULAR IMMUNITY; CHILDHOOD MORTALITY; DRUG EFFICACY; DRUG INDICATION; GROUP B STREPTOCOCCAL INFECTION; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IMMUNOREGULATION; INFECTION SENSITIVITY; INFLUENZA; MATERNAL CARE; PERTUSSIS; PREGNANT WOMAN; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; TH1 TH2 BALANCE; TIME TO TREATMENT; FEMALE; FETUS BLOOD; IMMUNOLOGY; PRACTICE GUIDELINE; PREGNANCY; STANDARDS;

FEMALE; FETAL BLOOD; HUMANS; IMMUNIZATION; INFLUENZA VACCINES; PERTUSSIS VACCINE; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; VACCINES;

EID: 85016978145     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1509044     Document Type: Review

References (78)

1. The Millennium Development Goals Report. New York: United Nations, July 1, 2015 (http://www.un.org/millenniumgoals/2015-MDG-Report/pdf/MDG%202015%20rev%20(July%201).pdf).
2. Kourtis AP, Read JS, Jamieson DJ. Pregnancy and infection. N Engl J Med 2014; 370: 2211-8.
3. Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol 1996; 36(5): 248-55.
4. Straub RH. The complex role of estrogens in inflammation. Endocr Rev 2007; 28: 521-74.
5. Szekeres-Bartho J, Wegmann TG. A progesterone-dependent immunomodulatory protein alters the Th1/Th2 balance. J Reprod Immunol 1996; 31: 81-95.
6. Robinson DP, Klein SL. Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis. Horm Behav 2012; 62: 263-71.
7. Pazos M, Sperling RS, Moran TM, Kraus TA. The influence of pregnancy on systemic immunity. Immunol Res 2012; 54: 254-61.
8. Hulka JF. Effectiveness of polyvalent influenza vaccine in pregnancy: report of a controlled study during an outbreak of Asian influenza. Obstet Gynecol 1964; 23: 830-7.
9. Murray DL, Imagawa DT, Okada DM, St Geme JW Jr. Antibody response to monovalent A/New Jersey/8/76 influenza vaccine in pregnant women. J Clin Microbiol 1979; 10: 184-7.
10. Christian LM, Porter K, Karlsson E, Schultz-Cherry S, Iams JD. Serum proinflammatory cytokine responses to influenza virus vaccine among women during pregnancy versus non-pregnancy. Am J Reprod Immunol 2013; 70: 45-53.
11. Grosheide PM, Schalm SW, van Os HC, Fetter WP, Heijtink RA. Immune response to hepatitis B vaccine in pregnant women receiving post-exposure prophylaxis. Eur J Obstet Gynecol Reprod Biol 1993; 50: 53-8.
12. Schlaudecker EP, McNeal MM, Dodd CN, Ranz JB, Steinhoff MC. Pregnancy modifies the antibody response to trivalent influenza immunization. J Infect Dis 2012; 206: 1670-3.
13. Sperling RS, Engel SM, Wallenstein S, et al. Immunogenicity of trivalent inactivated influenza vaccination received during pregnancy or postpartum. Obstet Gynecol 2012; 119: 631-9.
14. Munoz FM, Bond NH, Maccato M, et al. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. JAMA 2014; 311: 1760-9.
15. Nasidi A, Monath TP, Vandenberg J, et al. Yellow fever vaccination and pregnancy: a four-year prospective study. Trans R Soc Trop Med Hyg 1993; 87: 337-9.
16. Bischoff AL, Følsgaard NV, Carson CG, et al. Altered response to A(H1N1) pnd09 vaccination in pregnant women: a single blinded randomized controlled trial. PLoS One 2013; 8(4): e56700.
17. Scheller NM, Pasternak B, Mølgaard-Nielsen D, Svanström H, Hviid A. Quadrivalent HPV vaccination and the risk of adverse pregnancy outcomes. N Engl J Med 2017; 376:1223-33.
18. Tapia MD, Sow SO, Tamboura B, et al. Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial. Lancet Infect Dis 2016; 16: 1026-35.
19. Chaithongwongwatthana S, Yamasmit W, Limpongsanurak S, Lumbiganon P, Tolosa JE. Pneumococcal vaccination during pregnancy for preventing infant infection. Cochrane Database Syst Rev 2015; 1: CD004903.
20. Burney LE. Influenza immunization: statement. Public Health Rep 1960; 75: 944.
21. Vaccines against influenza WHO position paper - November 2012. Wkly Epidemiol Rec 2012; 87: 461-76.
22. Deaths from Asian influenza, 1957; a report by the Public Health Laboratory Service based on records from hospital and public health laboratories. Br Med J 1958; 1: 915-9.
23. Jamieson DJ, Honein MA, Rasmussen SA, et al. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet 2009; 374: 451-8.
24. Van Kerkhove MD, Vandemaele KA, Shinde V, et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. PLoS Med 2011; 8(7): e1001053.
25. The ANZIC Influenza Investigators. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 2009; 361: 1925-34.
26. Mosby LG, Rasmussen SA, Jamieson DJ. 2009 pandemic influenza A (H1N1) in pregnancy: a systematic review of the literature. Am J Obstet Gynecol 2011; 205: 10-8.
27. Creanga AA, Kamimoto L, Newsome K, et al. Seasonal and 2009 pandemic influenza A (H1N1) virus infection during pregnancy: a population-based study of hospitalized cases. Am J Obstet Gynecol 2011; 204: Suppl 1: S38-S45.
28. Neuzil KM, Reed GW, Mitchel EF, Simonsen L, Griffin MR. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol 1998; 148: 1094-102.
29. Martin A, Cox S, Jamieson DJ, Whiteman MK, Kulkarni A, Tepper NK. Respiratory illness hospitalizations among pregnant women during influenza season, 1998-2008. Matern Child Health J 2013; 17: 1325-31.
30. Hartert TV, Neuzil KM, Shintani AK, et al. Maternal morbidity and perinatal outcomes among pregnant women with respiratory hospitalizations during influenza season. Am J Obstet Gynecol 2003; 189: 1705-12.
31. Dodds L, McNeil SA, Fell DB, et al. Impact of influenza exposure on rates of hospital admissions and physician visits because of respiratory illness among pregnant women. CMAJ 2007; 176: 463-8.
32. Schanzer DL, Langley JM, Tam TW. Influenza-attributed hospitalization rates among pregnant women in Canada 1994-2000. J Obstet Gynaecol Can 2007; 29: 622-9.
33. Bhat N, Wright JG, Broder KR, et al. Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med 2005; 353: 2559-67.
34. Moriarty LF, Omer SB. Infants and the seasonal influenza vaccine: a global perspective on safety, effectiveness, and alternate forms of protection. Hum Vaccin Immunother 2014; 10: 2721-8.
35. Chu HY, Englund JA. Maternal immunization. Clin Infect Dis 2014; 59: 560-8.
36. Omer SB, Richards JL, Madhi SA, et al. Three randomized trials of maternal influenza immunization in Mali, Nepal, and South Africa: methods and expectations. Vaccine 2015; 33: 3801-12.
37. Zaman K, Roy E, Arifeen SE, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008; 359: 1555-64.
38. Madhi SA, Cutland CL, Kuwanda L, et al. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med 2014; 371: 918-31.
39. Steinhoff M, Tielsch J, Katz J, et al. Evaluation of year-round maternal influenza immunization in tropical SE Asia: a placebo-controlled randomized trial. Open Forum Infect Diss 2015; 2: Suppl 1. abstract.
40. Steinhoff MC, Omer SB, Roy E, et al. Neonatal outcomes after influenza immunization during pregnancy: a randomized controlled trial. CMAJ 2012; 184: 645-53.
41. O'Brien KL, Walters MI, Sellman J, et al. Severe pneumococcal pneumonia in previously healthy children: the role of preceding influenza infection. Clin Infect Dis 2000; 30: 784-9.
42. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 2008; 198: 962-70.
43. Omer SB, Zaman K, Roy E, et al. Combined effects of antenatal receipt of influenza vaccine by mothers and pneumococcal conjugate vaccine receipt by infants: results from a randomized, blinded, controlled trial. J Infect Dis 2013; 207: 1144-7.
44. van Santen KL, Bednarczyk RA, Adjaye-Gbewonyo D, Orenstein WA, Davis R, Omer SB. Effectiveness of pneumococcal conjugate vaccine in infants by maternal influenza vaccination status. Pediatr Infect Dis J 2013; 32: 1180-4.
45. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women - Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 2013; 62: 131-5.
46. Vaccination against pertussis (whooping cough) for pregnant women - 2016: information for healthcare professionals. London: Public Health England, 2016.
47. Hakin B, Cosford P, Harvey F. Continuation of temporary programme of pertussis (whooping cough) vaccination of pregnant women. London: Public Health England, 2013.
48. Amirthalingam G, Andrews N, Campbell H, et al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet 2014; 384: 1521-8.
49. Dabrera G, Amirthalingam G, Andrews N, et al. A case-control study to estimate the effectiveness of maternal pertussis vaccination in protecting newborn infants in England and Wales, 2012-2013. Clin Infect Dis 2015; 60: 333-7.
50. Kharbanda EO, Vazquez-Benitez G, Lipkind HS, et al. Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes. JAMA 2014; 312: 1897-904.
51. Sukumaran L, McCarthy NL, Kharbanda EO, et al. Safety of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis and influenza vaccinations in pregnancy. Obstet Gynecol 2015; 126: 1069-74.
52. Sukumaran L, McCarthy NL, Kharbanda EO, et al. Association of Tdap vaccination with acute events and adverse birth outcomes among pregnant women with prior tetanus-containing immunizations. JAMA 2015; 314: 1581-7.
53. Jones C, Pollock L, Barnett SM, Battersby A, Kampmann B. The relationship between concentration of specific antibody at birth and subsequent response to primary immunization. Vaccine 2014; 32: 996-1002.
54. Englund JA, Anderson EL, Reed GF, et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics 1995; 96: 580-4.
55. Halperin SA, Halperin B, Allen VM, Langley J, McNeil S, Li L. Safety and immunogenicity of tetanus-diphtheria-acellular pertussis vaccine (Tdap) during pregnancy. Presented at the 19th Annual Conference on Vaccine Research, Baltimore, April 18-20, 2016. abstract.
56. Hoang HT, Leuridan E, Maertens K, et al. Pertussis vaccination during pregnancy in Vietnam: results of a randomized controlled trial. Vaccine 2016; 34: 151-9.
57. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375: 1545-55.
58. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-128.
59. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009; 360: 588-98.
60. RSV vaccine snapshot. PATH Vaccine Resource Library, 2016 (http://www.path.org/vaccineresources/details.php?i=1562).
61. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89: 422-34.
62. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 1969; 89: 435-48.
63. Acosta PL, Caballero MT, Polack FP. Brief history and characterization of enhanced respiratory syncytial virus disease. Clin Vaccine Immunol 2015; 23: 189-95.
64. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102: 531-7.
65. Glenn GM, Fries LF, Thomas DN, et al. A randomized, blinded, controlled, doseranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age. J Infect Dis 2016; 213: 411-22.
66. Glenn GM, Smith G, Fries L, et al. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine 2013; 31: 524-32.
67. Phares CR, Lynfield R, Farley MM, et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA 2008; 299: 2056-65.
68. Healy CM, Baker CJ. Streptococcus group B vaccines A2. In: Plotkin, SA, Orenstein WA, Offit PA, eds. Vaccines. 6th ed. London: W.B. Saunders, 2013: 1176-81.
69. Ahmadzia HK, Heine RP. Diagnosis and management of group B streptococcus in pregnancy. Obstet Gynecol Clin North Am 2014; 41: 629-47.
70. Regan JA, Klebanoff MA, Nugent RP. The epidemiology of group B streptococcal colonization in pregnancy. Obstet Gynecol 1991; 77: 604-10.
71. Madhi SA, Cutland CL, Jose L, et al. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial. Lancet Infect Dis 2016; 16: 923-34.
72. Madhi SA, Dangor Z, Heath PT, et al. Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants. Vaccine 2013; 31: Suppl 4: D52-D57.
73. Munoz FM, Ferrieri P, Group B. Group B streptococcus vaccination in pregnancy: moving toward a global maternal immunization program. Vaccine 2013; 31: Suppl 4: D46-D51.
74. Donders GG, Halperin SA, Devlieger R, et al. Maternal immunization with an investigational trivalent group B streptococcal vaccine: a randomized controlled trial. Obstet Gynecol 2016; 127: 213-21.
75. Heyderman RS, Madhi SA, French N, et al. Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, openlabel, multicentre trial. Lancet Infect Dis 2016; 16: 546-55.
76. Edmond KM, Kortsalioudaki C, Scott S, et al. Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet 2012; 379: 547-56.
77. Ding H, Black CL, Ball S, et al. Influenza vaccination coverage among pregnant women - United States, 2014-15 influenza season. MMWR Morb Mortal Wkly Rep 2015; 64: 1000-5.
78. Ahluwalia IB, Ding H, D'Angelo D, et al. Tetanus, diphtheria, pertussis vaccination coverage before, during, and after pregnancy - 16 states and New York City, 2011. MMWR Morb Mortal Wkly Rep 2015; 64: 522-6.